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Objective: We aimed to clarify the association of various HLA risk alleles with different types of 
autoantibodies initiating islet specific autoimmunity.  
Methods: Follow-up cohorts from the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) 
study and children diagnosed with type 1 diabetes from the Finnish Pediatric Diabetes Register 
(FPDR) were analyzed for the presence of autoantibodies to insulin (IAA), glutamic acid 
decarboxylase (GADA), IA-2 antigen (IA-2A) and zinc transporter 8 (ZnT8A) and genotyped for HLA 
DR/DQ alleles.  In the DIPP study autoantibodies were regularly analyzed from birth up to 15 years 
of age. 
Results: In the DIPP cohort 621 children developed one single persistent autoantibody, GADA in 
284, IAA in 268 and IA-2A in 40 cases. Highly significant differences in the specificity of the first 
autoantibody were observed between HLA genotypes.  Homozygotes for the DR3-DQ2 haplotype 
had almost exclusively GADA as the first autoantibody whereas a more even distribution between 
GADA and IAA was found in DR3-DQ2/DR4-DQ8 as well as DR3-DQ/x and DR4-DQ8/x genotypes (x 
referring to neutral haplotypes). In DR4-DQ8 positive genotypes with the DRB1*04:01 allele IAA 
was more often the first autoantibody than in DRB1*04:04 positive genotypes. Various neutral 
haplotypes also significantly affected the relative proportions of different initial autoantibodies. 
These findings were confirmed and expanded in a series of 1591 T1D children under the age of 10 
years from FPDR. 
Conclusions:  These results emphasize the importance of HLA class II polymorphisms in the 
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1  INTRODUCTION 
 
Susceptibility to type 1 diabetes (T1D) is strongly associated with polymorphisms in HLA class II 
genes. Various alleles especially in HLA-DR and -DQ loci and their specific combinations are 
associated either with an increased risk or protection against disease development1,2. Immune 
responses including islet specific autoimmunity are initiated when CD4+ T cells recognize specific 
antigen epitopes bound by HLA class II molecules on the surface of antigen presenting cells. The 
allelic variability in the capacity to bind and present various critical peptide epitopes most 
probably explains the disease associations between HLA alleles and multiple diseases3.  
Heterogeneity in the pathogenic mechanisms of T1D has long been suspected based on the 
association with two major HLA class II haplotypes4. HLA DR3-DQ2 and DR4-DQ8 are both 
associated with disease risk and the genotype combining both haplotypes confers a strongly 
increased risk higher than homozygosity for either haplotype2. Recent follow-up studies of 
children with genetic susceptibility to type 1 diabetes have also supported heterogeneity. In most 
cases either insulin autoantibodies (IAA) or autoantibodies specific for glutamic acid decarboxylase 
65 (GADA) are the first autoantibodies to appear reflecting the development of islet specific 
autoimmunity. Subjects with IAA as the initial autoantibody are more often positive for the HLA 
DR4-DQ8 haplotype and the T1D associated INS gene genotype and the peak age at the 
seroconversion is in early childhood before the age of 2 years whereas the appearance of GADA 
starts usually later in childhood and continues at higher level up to the adulthood. GADA-initiated 
autoimmunity is typically associated with the HLA DR3-DQ2 haplotype and is not associated with 
the presence of INS risk genotype but instead T1D associated alleles within the IKZF4/ERBB3 gene 
region5,6. These differences suggest heterogeneity in the pathogenetic processes and 
environmental influences triggering islet autoimmunity and β-cell destruction. 
In this study we wanted to further characterize the diversity of HLA associations between 
children developing different islet specific autoantibodies initializing the autoimmune process by 
analyzing HLA DR-DQ genotypes including variations between various DR4 subtypes in DR4-DQ8 
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haplotypes and various “neutral” HLA-DR-DQ haplotypes in children followed in the Finnish 
Diabetes Prediction and Prevention (DIPP) study7. The obtained results were further confirmed 
and expanded in the series of recently diagnosed children from the Finnish Pediatric Diabetes 
Register (FPDR) who at diagnosis had autoantibody combinations strongly suggesting presence of 
either IAA, GADA or IA-2A as the first single autoantibody at the initiation of autoimmunity8. 
 
 
2  METHODS 
 
2.1  Study subjects 
 
The study subjects were recruited in the Finnish DIPP (ClinicalTrials.gov Identifier: NCT03269084) 
and FPDR9 studies. A written informed consent was required for all participants from a parent or 
legal guardian. The Ethics Committees at the three participating University Hospitals, Turku, Oulu 
and Tampere in DIPP study and The Ethics Committee of the Hospital District of Helsinki and 
Uusimaa in FPDR have approved the study protocols.  
 Two separate cohorts with somewhat different eligibility criteria and length of follow-up were 
analyzed in the DIPP follow-up study. The first cohort was recruited from November 1994 to 
August 2004 and included 9297 children with at least three visits for the measurements of 
autoantibodies. Among them there were 497 children who had only one specific autoantibody 
present at the initiation of persistent islet specific autoimmunity. Originally all children with 
DQB1*02/DQB1*03:02 and DQB1*03:02/x (x any allele except DQB1*02, DQB1*03:01 or 
DQB1*06:02/03) genotypes were eligible but beginning from April 1997 DQB1*06:02 and 
DQB1*06:03 alleles were differentiated and children with DQB1*03:02/DQB1*06:02 were 
excluded but those with DQB1*03:02/DQB1*06:03 were eligible. In one of the three centers also 
boys with the DQA1*05-DQB1*02/x (x any allele except DQB1*03:01, DQB1*03:02, DQB1*06:02, 
DQB1*06:03 or DQA1*02:01-DQB1*02 combination) genotype were recruited since January 1998.  
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 Another DIPP cohort was recruited from March 2010 to the end of year 2015 included 3377 
children with at least three visits for the analysis of autoantibodies, and persistent islet specific 
autoimmunity with only one specific autoantibody present was detected in 124 children. Eligible 
genotypes included combinations of HLA DQA1*05-DQB1*02 (DR3-DQ2) and 
DRB1*04:01/02/04/05-DQA1*03-DQB1*03:02 haplotypes (DR4-DQ8), homozygosity for DR3-DQ2 
or DR4-DQ8 haplotypes as well as DRB1*04:01/02/05-DQA1*03-DQB1*03:02 in combinations with 
either the DQB1*05:01 (DR1-DQ5), DQA1*02:01-DQB1*02 (DR7-DQ2), DQB1*04 (DR8-DQ4), 
(DQA1*03-DQB1*03:03 (DR9-DQ9) or DQB1*06:04 (DR13-DQ6.4) haplotype and the DR3-
DQ2/DR9-DQ9 combination.  
 Both cohorts were followed for the appearance of autoantibodies either until to the age of 15 
years or until April 2017. In addition to these cohorts we analyzed 3355 children from the Finnish 
Pediatric Diabetes Register (FPDR) who had been diagnosed with T1D before the age of 10 years 
and who had been tested for the presence of islet autoantibodies and genotyped for HLA-DR/DQ 
loci. Autoantibody patterns suggesting presence of either IAA, GADA or IA-2A as the first 
autoantibody were identified in 1559 children (46.5%).  These patterns were observed to associate 
with either insulin, GADA or IA-2A being the first autoantibody initializing autoimmunity in the 
earlier follow-up study of 128 children in the DIPP project who were followed from birth up to the 
diagnosis of T1D8. As IAA and GADA were the two most common autoantibodies to appear as the 
first autoantibody (106/128, 82.8%), IAA could be deduced to be usually the first autoantibody 
detected in cases where  IAA was present at diagnosis but not GADA, and similarly GADA without 
IAA could be deduced in most cases to be the first autoantibody and this was also confirmed in the 
study. IA-2A was  found to be the first autoantibody in 13 (10.2%) cases and ZnT8A in nine (7.0%) 
cases. In seven (53.8%) of the 13 cases in whom IA-2A was the first autoantibody it was also the 
only autoantibody present at  diagnosis. Although IA-2A present as the only autoantibody at 
diagnosis implied that that antibody was the first autoantibody detected, this association was 
weaker than the associations in autoantibody combinations suggesting presence of IAA or GADA 
as the first autoantibody. Due to the increasing number of inverse seroconversions by increasing 
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follow-up time especially in the group with IAA as the first autoantibody we decided to include 
only children diagnosed before the age of 10 years into the analysis. 
 
 
2.2 HLA typing 
 
All available autoantibody positive samples in the DIPP follow-up cohort and samples of the FPDR 
were analyzed for HLA-DR/DQ haplotypes present using a step-wise method starting with DQB1 
alleles and continuing with DQA1 when informative and also with HLA-DR4 subtyping if relevant. 
This typing procedure based on various procedures using sequence specific lanthanide-labelled 
oligonucleotides defines major DR/DQ haplotypes found in populations of European ancestry and 
differentiates DRB1, DQA1 and DQB1 loci at four digit level when relevant for T1D risk10. 
 
 
2.3 Autoantibody analysis 
 
In the DIPP cohort serum samples were originally screened for islet cell autoantibodies (ICA) using 
immunofluorescence staining of human pancreas preparations and in the case of ICA positivity, all 
samples from such subjects were studied for IAA, GADA and IA-2A using radio-binding assays. 
Since year 2003, these three biochemical autoantibodies were used for primary screening. In 
addition, all sera from the first 1004 enrolled DIPP children born between November 1994 and July 
1997 were analyzed for these three biochemical autoantibodies. In the earlier DIPP cohort, sera 
from subjects positive for IAA, GADA and/or IA-2A were also analyzed for ZnT8A autoantibodies. 
 In the FPDR, sera taken at the diagnosis (from 2 months before until 2 weeks after the 
diagnosis date) of children were analyzed for IAA, GADA, IA-2A and ZnT8A. Similar assays for 
autoantibody detection were used in both DIPP and FPDR samples but the analyses for IAA, GADA 
and IA-2A were carried out in different laboratories and thus slightly different cut-off values were 
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used. Details of the assays are published earlier as well as the results of these laboratories in 
autoantibody standardization programs11-14.  
 
 
2.4  Statistical analysis 
 
Chi-square test of independence was used in the comparison of groups with various HLA 
genotypes and first islet specific autoantibodies. Spreadsheet program used for analyzing the 
distribution was obtained from the address:  
http://www.biostathandbook.com/chiind.html (The Handbook of Biological Statistics, John H. 






3  RESULTS 
 
3.1  Follow-up cohorts in the DIPP study 
 
A total of 497 children in the DIPP cohort recruited from November 1994 to September 2004 had 
developed a single first persistent autoantibody, a majority of them either GADA or IAA. IA-2A and 
ZnT8A were relatively rare as the first autoantibodies. However, ZnT8A was measured only from 
subjects who were also positive for some other biochemical autoantibodies and thus the number 
would be apparently higher if all children had been tested.  
 When the distribution of the first autoantibodies initializing islet autoimmunity were 
compared between children with different major HLA risk genotypes based on the presence of the 
DR3-DQ2 and/or DR4-DQ8 haplotypes highly significant differences were detected (Figure 1A, 
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P=0.000019, df=12). GADA was found as the first autoantibody in five (83%) of six children 
homozygous for DR3-DQ2 and GADA was the most common first autoantibody also among those 
with the DR3-DQ2/DR4-DQ8 (52.2%) and DR4-DQ8/DR4-DQ8 (59.3%) genotypes, whereas IAA was 
most often the first autoantibody among those with DR3-DQ2/x (36.8%) and DR4-DQ8/x 
genotypes (47.2%) genotypes. IA-2A was rarely the first autoantibody. It was most common in 
DR4-DQ8 homozygotes and in those carrying DR3-DQ2/x genotype albeit the numbers were small. 
The later DIPP cohort recruited since March 2010 was similarly analyzed for the appearance of 
various islet specific autoantibodies in different HLA genotypes. In this cohort eligibility criteria 
were somewhat different and mean follow-up time shorter than in the old cohort and ZnT8 
autoantibody results were not available from this cohort. Thus, the analyses of two cohorts were 
made separately. Also in this cohort a highly significant difference was found between the major 
HLA risk genotypes (Figure 1b, P = .000067, df = 8). Recruitment of DR3-DQ2 homozygotes in all 
centers during this period increased their numbers and confirmed the finding of the very strong 
association of this genotype with GADA as the first autoantibody. In contrast, in both cohorts 
children with the DR3-DQ2/x genotype (which in fact was just the DR3-DQ2/DR9-DQ9 genotype in 
the later cohort) were not dominated by GADA initiated autoimmunity like in DR3-DQ2 
homozygotes.  
Children with the DR4-DQ8/x genotype in both cohorts had IAA as the most common first 
autoantibody and especially in the newer cohort the dominance of IAA was obvious. This is 
probably caused by the fact that in the newer cohort only children positive for DRB1*04:01/2/5 
alleles in the DR4-DQ8 haplotypes (mainly DRB1*04:01) were eligible in this group. In the earlier 
cohort comparison of children with either DRB1*04:01 or DRB1*04:04 positive DR4-DQ8 
haplotypes in the DR4-DQ8/x genotype demonstrated that in DRB1*04:01 positive children IAA 
was more often the first autoantibody, whereas in children with DRB1*04:04 positive genotypes 
GADA was most often the first autoantibody (P =.0073, df = 2, Table 1). When various 
combinations of DRB1*04:01 and DRB1*04:04 were compared among homozygous DR4-DQ8 
positive subjects from combined cohorts IAA was the first autoantibody in ten of 27 children with 
DRB1*04:01 homozygosity whereas it was found only in four of 34 cases homozygous for 
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DRB1*04:04 or with the DRB1*04:01/DRB1*04:04 genotype (P = .043) emphasizing the association 
of IAA with the DRB1*04:01-DQB1*03:02 haplotype. 
 
 
3.2  Antibody patterns at the diagnosis of type 1 diabetes in children below the age of 10 years 
 
Autoantibody data at the diagnosis of T1D were available from 3355 children who were diagnosed 
below the age of 10 years in FPDR. Autoantibody patterns at the diagnosis suggested presence of 
either GADA, IAA or IA-2A as the first autoantibody in 1559 of them8. Comparison of these groups 
for the main HLA-DR/DQ genotypes confirmed the strong heterogeneity (P = 8.5E-12, df = 10) and 
the clear association of the DR3-DQ2/x genotype in addition to  DR3-DQ2/DR3-DQ2 homozygosity 
with the “GADA group” (Figure 2). The proportion of autoantibody combinations suggesting IAA as 
the first autoantibody was highest among DR4-DQ8 positive genotypes including DR3-DQ2/DR4-
DQ8, DR4-DQ8/DR4-DQ8 and DR4-DQ8/x although GADA was still the most common implicated 
first autoantibody in all of them. IA-2A alone indicating that antibody as the first autoantibody was 
especially rare among children homozygous for DR3-DQ2 and with DR3-DQ2/x genotype. The 
genotype group x/x without either DR3-DQ2 or DR4-DQ8 lacking from the follow-up cohorts 
showed their strongest association with GADA initiated autoimmunity but in addition also IAA and 
IA-2A were relatively common as first autoantibodies compared to DR3-DQ2/x  and DR3-DQ2 
homozygous groups.  
Further comparisons were performed only between children with autoantibody combinations 
suggesting either GADA or IAA as the first autoantibody because of the small number of  children 
with  IA-2A alone. Preferential association of DRB1*04:01 with IAA-initiated and DRB1*04:04 with 
GADA-initiated autoimmunity was apparent also when various DR4 subtypes were compared 
within homozygous DR4-DQ8 genotypes as well as within the DR3-DQ2/DR4-DQ8 and DR4-DQ8/x 
genotypes (Table 2).  
For the analysis of the effect of various neutral or protective haplotypes in combination with 
either DR3-DQ2 or two different DR4 alleles in DR4-DQ8/x genotypes only those genotypes with at 
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least five cases were included. Significant heterogeneity was detected among the carriers of the 
most frequent DRB1*04:01 positive DR4-DQ8/x genotype (P= .000083, df = 7) where DR13-DQ6.3, 
DR8-DQ4, DR13-DQ6.4 were more often associated with IAA than GADA as the first autoantibody 
whereas DR1/10-DQ5, DR4-DQ7, DR5-DQ7 and DR7-DQ2 were most often observed with GADA 
initiated autoimmunity (Table 3). Although no significant differences were detected in the 
distribution of neutral haplotypes between IAA and GADA initiated autoimmunity in the DR3-
DQ2/x and DRB1*04:04 positive DR4/x genotype, a tendency for a similar type of preferential  
association was seen (Table 3).  
Table 4 shows the associations of implicated GADA and IAA initiated autoantibody responses 
to genotypes where only neutral or protective haplotypes were present without any DR3-DQ2 or 
DR4-DQ8 haplotypes. Though relatively rare, we identified 191 children with such combinations in 
the FPDR series. There was a tendency of heterogeneity also among these genotypes. The 
antibody combinations implicating GADA as the first autoantibody were most common in all 
genotypes but the proportion of IAA was relatively high in genotypes where DR1/10-DQB1*05 was 




4  DISCUSSION 
 
The preferential association of IAA positivity with HLA DR4-DQ8 and GADA with HLA DR3-DQ2 
haplotype at diagnosis of T1D has been known for decades15-18 but follow-up studies have recently 
demonstrated that the association is even more strong when the first autoantibody initiating islet 
autoimmunity is considered6,19. This strong association agrees with the role of class II molecules in 
antigen presentation where differences in amino acids between various alleles affect the ability of 
different peptide epitopes to be bound and be presented to CD4+ T cells initiating the immune 
response20.  
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 Earlier studies have shown a high incidence of IAA-initiated autoimmunity in DR4-DQ8 
homozygous children and GADA-initiated autoimmunity in DR3-DQ2 homozygous children with a 
more even picture in children with the heterozygous DR3-DQ2/DR4-DQ8 genotype6,19. Most 
conspicuous was the dominance of GADA as the first autoantibody in DR3-DQ2 homozygotes, 
whereas in the group of DR4-DQ8 homozygotes also GADA was relatively frequently the first 
autoantibody. In the TEDDY study also a group of children with DR4-DQ8/DR8-DQ4 genotype was 
included with a strong dominance of IAA-initiated autoimmunity6. We now analyzed in the DIPP 
study various DR4 subtypes in DR4-DQ8 haplotypes which also differ for the strength of their 
association with T1D1,21. There was a clear difference between the two common DR4 alleles in 
Finland, DRB1*04:01 was more strongly associated with IAA initiated autoimmunity than 
DRB1*04:04 which was preferentially found among children with GADA as the first autoantibody.  
The difference was most pronounced when comparing DRB1*04:01 homozygous and 
DRB1*04:04 homozygous children but similarly detected in comparison of the DR4 subtype in 
DR3-DQ2/DR4-DQ8 heterozygotes and in the DR4-DQ8/x genotype. Differences between various 
DR4 subtypes in preferential autoantigen recognition are in accordance with findings where  islet 
autoantigen epitopes have been presented to specific CD4+ T cell by either DRB1*04:0122  or 
DB1*04:0423  alleles but also by both of these alleles24.  An important difference between these 
two alleles is also seen in the probability to develop autoantibodies against 21-OH hydroxylase and 
Addison´s disease detected together with T1D in autoimmune polyendocrine syndrome 2. Besides 
the major DR3-DQ2 association, antibodies to 21- hydroxylase and Addison´s disease are 
associated only with DRB1*04:04 and not with the DRB1*04:01 positive DR4-DQ8 haplotypes 
despite stronger association of T1D with DRB1*04:0125,26 
 Due to the strong linkage between DR and DQ loci the actual molecules responsible for the 
initiation of autoimmunity reflected in circulating autoantibodies is not easy to define but our 
observation on the importance of DR4 subtypes in DR4-DQ8 haplotypes supports the importance 
of also DR molecules besides DQ similarly to the known genetic associations of alleles in both 
molecules. 
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In addition to the class II molecules in the known risk associated DR3-DQ2 and DR4-DQ8 
haplotypes, neutral haplotypes affected the specificity of the first autoantibody to appear. This 
was demonstrated by the increase of IAA-initiated autoantibody response in subjects with a 
genotype where DR3-DQ2 was associated with some of these neutral haplotypes compared to the 
nearly exclusive GADA-initiated autoimmunity in DR3-DQ2 homozygotes. When genotypes 
combining various neutral haplotypes with either DR3-DQ2 or DR4-DQ8 risk haplotypes were 
compared at diagnosis for autoantibody combinations implicating either IAA or GADA as the initial 
autoantibody the strongest differences were observed in the largest group with  DRB1*0401 
positive DR4-DQ8/x genotypes but similar tendencies of IAA or GADA associations were also seen 
in DRB1*04:04 positive DR4-DQ8/x and DR3-DQ2/x genotypes as well as in genotypes where only 
neutral or slightly protective haplotypes were present although the number of children with 
numerous different genotype combinations was too low for any definitive results.   
There are limitations of the current study. ZnT8 autoantibodies were analyzed only in children 
testing positive for other islet specific autoantibodies in the first DIPP follow-up cohort and not at 
all in the later DIPP cohort. It was anyway rare in subjects who developed also other 
autoantibodies which is the case for the majority of cases eventually developing T1D. Similar 
results obtained in both DIPP follow-up cohorts for the differences in genetic associations of major 
IAA- and GADA-initiated groups also indicate that ZnT8A is relatively rare as initial autoantibody in 
islet specific autoimmunity. Associations of IAA and GADA initiated autoantibody responses with 
different major HLA risk genotypes, importantly  including DR4 subtypes, were also supported by 
the data obtained from autoantibody combinations at diagnosis suggesting either IAA or GADA 
being the first islet specific autoantibody. These autoantibody combinations can be, however, 
identified only in less than half of children diagnosed with T1D and because the tendency of IAA to 
disappear with the increasing duration of the follow-up, the possibility for deduction is limited to 
the youngest age group. Sera obtained at diagnosis of T1D are easily available in high numbers 
compared to follow-up studies starting in early childhood and may also supply genotypes less 
common in T1D, which are not selected in genetic screening for follow-up studies. However, more 
comparisons of initial autoantibodies and autoantibodies at diagnosis are still needed from follow-
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up studies. The results obtained anyway demonstrate that based on autoantibody analyses at 
diagnosis a large proportion of prepubertal cases can be identified with a reasonable accuracy to 
have either IAA- or GADA-initiated autoimmunity. These “endotypes” have strong associations 
with different HLA risk genotypes and using various sample series and information collected at 
diagnosis can produce more information on genetics and immunological features as well as 
demography and epidemiology associated with these two major forms of islet specific 
autoimmunity in childhood.  
In conclusion, the strong association between the specificity of first islet autoantibody to 
appear and the HLA class II genotypes supports the hypothesis that recognition of a limited 
number of autoantigen epitopes is crucial in the initiation of the pathogenic process and may 
furthermore explain specific class II HLA associations with possible environmental effects 





The authors thank the dedicated personnel of the Finnish Type 1 DIPP Study and the Finnish 
Pediatric Diabetes Register as well as the participating children and their families. The study was 






1. Erlich H, Valdes AM, Noble J, et al. HLA DR-DQ haplotypes and genotypes and type 1 
diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes. 
2008;57(4):1084-1092. 
This article is protected by copyright. All rights reserved.
2. Thomson G, Valdes AM, Noble JA, et al. Relative predispositional effects of HLA class II 
DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. Tissue 
Antigens. 2007;70(2):110-127. 
3. Howell WM. HLA and disease: guilt by association. Int J Immunogenet. 2014;41(1):1-12. 
4. Ludvigsson J, Samuelsson U, Beauforts C, et al. HLA-DR 3 is associated with a more slowly 
progressive form of type 1 (insulin-dependent) diabetes. Diabetologia. 1986;29(4):207-210. 
5. Ilonen J, Hammais A, Laine AP, et al. Patterns of β-cell autoantibody appearance and 
genetic associations during the first years of life. Diabetes. 2013;62(10):3636-3640. 
6. Krischer JP, Lynch KF, Schatz DA, et al. The 6 year incidence of diabetes-associated 
autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia. 
2015;58(5):980-987. 
7. Bauer W, Veijola R, Lempainen J, et al. Age at Seroconversion, HLA Genotype, and 
Specificity of Autoantibodies in Progression of Islet Autoimmunity in Childhood. J Clin 
Endocrinol Metab. 2019;104(10):4521-4530. 
8. Ilonen J, Lempainen J, Hammais A, et al. Primary islet autoantibody at initial 
seroconversion and autoantibodies at diagnosis of type 1 diabetes as markers of disease 
heterogeneity. Pediatr Diabetes. 2018;19(2):284-292. 
9. Parkkola A, Härkönen T, Ryhänen SJ, Ilonen J, Knip M, the Finnish Pediatric Diabretes 
Regisdter. Extended family history of type 1 diabetes and phenotype and genotype of 
newly diagnosed children. Diabetes Care 2013;36:348-354 
10. Ilonen J, Kiviniemi M, Lempainen J, et al. Genetic susceptibility to type 1 diabetes in 
childhood - estimation of HLA class II associated disease risk and class II effect in various 
phases of islet autoimmunity. Pediatr Diabetes. 2016;17 Suppl 22:8-16. 
11. Juusola M, Parkkola A, Härkönen T, et al. Positivity for Zinc Transporter 8 Autoantibodies at 
Diagnosis Is Subsequently Associated With Reduced β-Cell Function and Higher Exogenous 
Insulin Requirement in Children and Adolescents With Type 1 Diabetes. Diabetes Care. 
2016;39(1):118-121. 
12. Turtinen M, Härkönen T, Parkkola A, Ilonen J, Knip M, Finnish Pediatric Diabetes Register. 
Sex as a determinant of type 1 diabetes at diagnosis. Pediatr Diabetes. 2018;19(7):1221-
1228. 
13. Siljander HT, Simell S, Hekkala A, et al. Predictive characteristics of diabetes-associated 
autoantibodies among children with HLA-conferred disease susceptibility in the general 
population. Diabetes. 2009;58(12):2835-2842. 
14. Pöllänen PM, Lempainen J, Laine AP, et al. Characterisation of rapid progressors to type 1 
diabetes among children with HLA-conferred disease susceptibility. Diabetologia. 
2017;60(7):1284-1293. 
15. Vandewalle CL, Decraene T, Schuit FC, De Leeuw IH, Pipeleers DG, Gorus FK. Insulin 
autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA 
DQA1*0301-DQB1*0302 haplotype at clinical type 1 (insulin-dependent) diabetes mellitus 
before age 10 years, but not at onset between age 10 and 40 years. The Belgian Diabetes 
Registry. Diabetologia. 1993;36(11):1155-1162. 
This article is protected by copyright. All rights reserved.
16. Ziegler R, Alper CA, Awdeh ZL, et al. Specific association of HLA-DR4 with increased 
prevalence and level of insulin autoantibodies in first-degree relatives of patients with type 
I diabetes. Diabetes. 1991;40(6):709-714. 
17. Sanjeevi CB, Falorni A, Kockum I, Hagopian WA, Lernmark A. HLA and glutamic acid 
decarboxylase in human insulin-dependent diabetes mellitus. Diabet Med. 1996;13(3):209-
217. 
18. Vandewalle CL, Falorni A, Lernmark A, et al. Associations of GAD65- and IA-2- 
autoantibodies with genetic risk markers in new-onset IDDM patients and their siblings. 
The Belgian Diabetes Registry. Diabetes Care. 1997;20(10):1547-1552. 
19. Giannopoulou EZ, Winkler C, Chmiel R, et al. Islet autoantibody phenotypes and incidence 
in children at increased risk for type 1 diabetes. Diabetologia. 2015;58(10):2317-2323. 
20. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med. 2000;343(10):702-709. 
21. Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes 
in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex 
families. Am J Hum Genet. 1996;59(5):1134-1148. 
22. Endl J, Otto H, Jung G, et al. Identification of naturally processed T cell epitopes from 
glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes 
of recent onset IDDM patients. J Clin Invest. 1997;99(10):2405-2415. 
23. Mannering SI, Pang SH, Williamson NA, et al. The A-chain of insulin is a hot-spot for CD4+ T 
cell epitopes in human type 1 diabetes. Clin Exp Immunol. 2009;156(2):226-231. 
24. Mannering SI, Harrison LC, Williamson NA, et al. The insulin A-chain epitope recognized by 
human T cells is posttranslationally modified. J Exp Med. 2005;202(9):1191-1197. 
25. Yu L, Brewer KW, Gates S, et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase 
autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab. 
1999;84(1):328-335. 
26. Gombos Z, Hermann R, Kiviniemi M, et al. Analysis of extended human leukocyte antigen 








The Finnish Pediatric Diabetes Register comprises the following investigators: 
Principal Investigator: Mikael Knip (Children’s Hospital, Helsinki University Hospital) 
Steering Committee: Per-Henrik Groop (Folkhälsan Research Center), Jorma Ilonen 
(Immunogenetics Laboratory, University of Turku), Timo Otonkoski (Children’s Hospital, Helsinki 
University Hospital), Riitta Veijola (Department of Pediatrics, Oulu University Hospital). 
Locally responsible investigators:  
Alar Abram (Department of Pediatrics, Kanta-Häme Central Hospital), Henrikka Aito (Department 
of Pediatrics, HUS Porvoo Hospital), Ivan Arkhipov (Department of Pediatrics, Mehiläinen Länsi-
Pohja Central Hospital), Elina Blanco-Sequeiros (Department of Pediatrics, Central Ostrobothnia 
Central Hospital), Jonas Bondestam (Department of Pediatrics, HUS Lohja Hospital), Markus 
Granholm (Department of Pediatrics, Jakobstad Hospital), Maarit Haapalehto-Ikonen (Department 
of Pediatrics, Rauma Hospital), Torsten Horn (Department of Pediatrics, Central Hospital of Central 
Finland), Hanna Huopio (Department of Pediatrics, Kuopio University Hospital), Joakim Janer 
(Department of Pediatrics, HUS Raasepori Hospital), Christian Johansson (Department of 
Pediatrics, Åland Central Hospital), Liisa Kalliokoski (Department of Pediatrics, Kainuu Central 
Hospital), Päivi Keskinen (Department of Pediatrics, Tampere University Hospital), Anne Kinnala 
(Department of Pediatrics, Turku University Central Hospital), Maarit Korteniemi (Department of 
Pediatrics, Central Hospital of Lapland), Hanne Laakkonen (Department of Pediatrics, HUS 
Hyvinkää Hospital), Jyrki Lähde (Department of Pediatrics, Satakunta Central Hospital), Päivi 
Miettinen (HUS New Children’s Hospital). Päivi Nykänen (Department of Pediatrics, Mikkeli Central 
Hospital), Erik Popov (Department of Pediatrics, Vaasa Central Hospital), Mari Pulkkinen 
(Department of Pediatrics, HUS Jorvi Hospital), Maria Salonen (Department of Pediatrics, 
Kymenlaakso Central Hospital), Pia Salonen (Department of Pediatrics, Päijät-Häme Central 
Hospital), Juhani Sankala (Department of Pediatrics, Savonlinna Central Hospital), Virpi Sidoroff 
(Department of Pediatrics, North Karelia Central Hospital), Anne-Maarit Suomi (Department of 
Pediatrics, South Ostrobothnia Central Hospital, Tuula Tiainen (Department of Pediatrics, South 
Karelia Central Hospital), Riitta Veijola (Department of Pediatrics, Oulu University Hospital) 
 
  
This article is protected by copyright. All rights reserved.
LEGENDS FOR THE FIGURES 
 
Figure 1. Distribution of the first autoantibodies initializing islet autoimmunity compared between 
children with different major HLA risk genotypes based on the presence of DR3-DQ2 and/or DR4-
DQ8 haplotypes. A significant difference between various HLA genotypes was detected both in the 
first DIPP follow-up cohort recruited between years 1994-2004 (A, P=0.000019. df=12) and the 
second cohort recruited between years 2010-2015 (B, P=0.000067, df=8). ZnT8 autoantibodies 
were measured only in the first cohort and only from subjects positive for IAA, GADA or IA-2A. 
 
Figure 2. Distribution of autoantibody patterns at the diagnosis suggesting presence of either GADA, 
IAA or IA-2A as the first autoantibody based on the Finnish Pediatric Diabetes Register- Significant 
difference between  various  HLA genotypes was detected (P=8.5E-12, df=10). 
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Table 1.  First single persistent autoantibodies initialising islet specific autoimmunity in DIPP 
children with the DR4-DQ8/x genotype and either DRB1*04:01 or DRB1*04:04 allele in the HLA-
DR4-DQ8 haplotype. Cohort of children recruited for the study from 1994 to 2004. x = other than 
the DR3-DQ2 or DR4-DQ8 haplotype. Most common first autoantibody in each genotype marked 
bold 
 











N % N % N % N 
DRB1*04:01 68 36.4 102 54.5 17 9.1 187 
DRB1*04:04 38 57.6 26 39.4 2 2.9 66 
P=0.0073, df=2 




Table 2.  Distribution of deduced initial islet specific autoantibodies in children with either 
DRB1*04:01/x or DRB1*04:04/x in various HLA-DR4-DQ8 genotypes. Autoantibodies measured 
from sera at the diagnosis of T1D in the Finnish Pediatric Diabetes Register. Most common 
deduced first autoantibody in each genotype marked bold  
 









DRB1*04 alleles N % N % N 
*04:01/*04:01 26 42.6 35 57.4 61 
*04:01/*04:04 27 71.1 11 28.9 38 
*04:04/*04:04 9 81. 8 2 18.2 11 









DRB1*04 allele N % N % N 
DRB1*04:01 120 54.5 100 45,5 220 









DRB1*04 alleles N % N % N 
DRB1*04:01 216 50.0 216 50.0 432 
DRB1*04:04 90 70.9 37 29.1 127 
P=0.000033, df=1 
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Table 3. Distribution of autoantibody combinations associated with various initial islet specific 
autoantibodies in genotypes where a “neutral” or “slightly protective” haplotype (X) is associated 
with DR3-DQ2 or DR4-DQ8 haplotypes with either the DRB1*04:01 or DRB1*04:04 subtype. 
Autoantibodies measured from sera at the diagnosis with T1D in the Finnish Pediatric Diabetes 
Register. Most common first autoantibody in each genotype marked bold. Only genotypes with a 
total frequency of at least five are included. 
 








DR3-DQ2/X N % N % N 
     DR1/10-DQ5 69 84.1 13 15.9 82 
     DR4-DQ7 5 83.3 1 16.7 6 
     DR5-DQ7 7 100.0 0 0.0 7 
     DR7-DQ2 4 80.0 1 20.0 5 
     DR13-DQ6.3 4 66.7 2 33.3 6 
     DR13-DQ6.4 12 57.1 9 42.9 21 
     DR16-DQ5 5 83.3 1 16.,7 6 
     DR8-DQ4 22 71.0 9 29.0 31 
     DR9-DQ9 17 58.6 12 41.4 29 








DR4-DQ8/x: DRB1*04:01  N % N % N 
     DR1/10-DQ5 80 58.4 57 41.6 137 
     DR4-DQ7 8 80.0 2 20.0 10 
     DR5-DQ7 14 93.3 1 6.7 15 
     DR7-DQ2 11 55.0 9 45.0 20 
     DR13-DQ6.3 13 32.5 27 67.5 40 
     DR13-DQ6.4 23 47.9 25 52.1 48 
     DR8-DQ4 51 38.9 80 61.1 131 









DR4-DQ8/x: DRB1*04:04 N % N % N 
     DR1/10-DQ5 34 73.9 12 26.1 46 
     DR5-DQ7 6 85.7 1 14.3 7 
     DR7-DQ2 6 85.7 1 14.3 7 
     DR15-DQ6.2 5 62.5 3 37.5 8 
     DR13-DQ6.3 4 57.1 3 42.9 7 
This article is protected by copyright. All rights reserved.
     DR13-DQ6.4 4 57.1 3 42.9 7 
     DR8-DQ4 20 62.5 12 37.5 32 
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Table 4. Distribution of autoantibody combinations associated with various initial islet specific 
autoantibodies in genotypes where only neutral and protective haplotypeps are present. 
Autoantibodies measured from sera at the diagnosis of T1D in the Finnish Pediatric Diabetes 
Register. Most common first autoantibody in each genotype is marked bold. Only genotypes with 
a total frequency of at least five are included. 
 








HLA-genotype N % N % N 
DR1/10-DQ5/DR1/10-DQ5 10 83.3 2 16.7 12 
DR1/10-DQ5/DR13-DQ6.4 10 71.4 4 28,6 14 
DR1/10-DQ5/DR4-DQ7 7 53.8 6 46.2 13 
DR1/10-DQ5/DR7-DQ2 4 80.0 1 20.0 5 
DR1/10-DQ5/DR5-DQ7 7 100.0 0 0.0 7 
DR1/10-DQ5/DR8-DQ4 14 70.0 6 30.0 20 
DR1/10-DQ5/DR9-DQ9 21 84.0 4 16.0 25 
DR13-DQ6.4/DR8-DQ4 3 60.0 2 40,0 5 
DR13.6.4/DR9-DQ9 8 100.0 0 0.0 8 
DR7-DQ2/DR8-DQ4 10 55.6 8 44.4 18 
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